JP2013515013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515013A5 JP2013515013A5 JP2012545019A JP2012545019A JP2013515013A5 JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5 JP 2012545019 A JP2012545019 A JP 2012545019A JP 2012545019 A JP2012545019 A JP 2012545019A JP 2013515013 A5 JP2013515013 A5 JP 2013515013A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- acid sequence
- antibody fragment
- fragment according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009906286 | 2009-12-24 | ||
| AU2009906286A AU2009906286A0 (en) | 2009-12-24 | Anti P2X7 receptor antibodies and fragments thereof | |
| PCT/AU2010/001741 WO2011075789A1 (en) | 2009-12-24 | 2010-12-23 | Antibodies to non-functional oligomeric p2x7 receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515013A JP2013515013A (ja) | 2013-05-02 |
| JP2013515013A5 true JP2013515013A5 (enExample) | 2014-02-13 |
| JP5992831B2 JP5992831B2 (ja) | 2016-09-14 |
Family
ID=44194835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545019A Active JP5992831B2 (ja) | 2009-12-24 | 2010-12-23 | 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8835609B2 (enExample) |
| EP (2) | EP3321285B1 (enExample) |
| JP (1) | JP5992831B2 (enExample) |
| CN (1) | CN102762595B (enExample) |
| AU (1) | AU2010336032C1 (enExample) |
| BR (1) | BR112012015561B1 (enExample) |
| CA (1) | CA2784345C (enExample) |
| ES (2) | ES2667003T3 (enExample) |
| WO (1) | WO2011075789A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2434490C (en) | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| CA2737126C (en) | 2007-09-14 | 2018-05-01 | Biosceptre International Limited | Novel p2x7 epitopes |
| JP5624885B2 (ja) | 2007-09-14 | 2014-11-12 | バイオセプター・インターナショナル・リミテッド | 細胞外体液中のプリン作動性（ｐ２ｘ）受容体 |
| ES2610225T3 (es) | 2008-07-04 | 2017-04-26 | Biosceptre (Aust) Pty Ltd | Péptidos y epítopos anti P2X7 |
| ES2557456T3 (es) | 2009-08-20 | 2016-01-26 | Biosceptre (Aust) Pty Ltd | Anticuerpos anti-receptor P2X7 y fragmentos de los mismos |
| AU2010336032C1 (en) | 2009-12-24 | 2016-04-21 | Biosceptre International Limited | Antibodies to non-functional oligomeric P2X7 receptors |
| CN106310245A (zh) | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
| US9566318B2 (en) * | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
| US20150239956A1 (en) * | 2012-06-27 | 2015-08-27 | Asahi Kasei Medical Co., Ltd. | High-affinity antibody and method for manufacturing the same |
| WO2016154683A1 (en) * | 2015-04-02 | 2016-10-06 | Biosceptre (Uk) Limited | Pain treatment |
| WO2017041143A1 (en) | 2015-09-11 | 2017-03-16 | Ctm@Crc Ltd. | Chimeric antigen receptors and uses thereof |
| EP3528789A4 (en) | 2016-10-21 | 2020-06-24 | Biosceptre UK Limited | CYTOTOXIC PARTICLES |
| JP2021518748A (ja) | 2018-02-23 | 2021-08-05 | アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ | カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体 |
| WO2019222796A1 (en) | 2018-05-21 | 2019-11-28 | Carina Biotech Pty Ltd | Chimeric antigen receptors with modified linker domains and uses thereof |
| WO2019229296A1 (en) | 2018-05-29 | 2019-12-05 | Teknologian Tutkimuskeskus Vtt Oy | Anti-thyroid hormone (t4) recombinant antibody or antigen binding fragment |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| EP4003531A1 (en) * | 2019-07-26 | 2022-06-01 | Biosceptre (Aust) Pty Ltd | P2x7 receptor targeted therapy |
| MX2023010646A (es) * | 2021-03-11 | 2023-11-30 | Biosceptre Aust Pty Ltd | Novedoso sistema de terapia celular. |
| CA3223086A1 (en) * | 2021-09-01 | 2023-03-09 | Patrick Schlegel | Methods and compositions for stimulating immune activity |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| EP0760850A1 (en) | 1994-05-27 | 1997-03-12 | Glaxo Group Limited | P2x RECEPTORS (PURINOCEPTOR FAMILY) |
| CA2228999A1 (en) | 1995-08-09 | 1997-02-20 | Institut National De La Sante Et De La Recherche Medicale | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis |
| EP0907729A1 (en) | 1996-04-30 | 1999-04-14 | Smithkline Beecham Plc | HUMAN P2x4 RECEPTOR SPLICE-VARIANTS |
| US6303338B1 (en) | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| EP2080802B1 (en) | 1998-06-01 | 2017-03-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| EP1157038A4 (en) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17) |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| AU1339701A (en) | 1999-10-22 | 2001-05-08 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
| AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| CA2434490C (en) | 2001-01-17 | 2014-06-03 | Intreat Pty Limited | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| AU2002322192B2 (en) | 2001-09-03 | 2008-05-01 | Biosceptre International Limited | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions |
| DK1473367T3 (da) | 2003-04-17 | 2007-10-01 | Affectis Pharmaceuticals Ag | Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser |
| CA2607541A1 (en) | 2005-05-05 | 2006-12-28 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
| US7767789B2 (en) | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2007027957A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US20100036101A1 (en) | 2006-10-10 | 2010-02-11 | Angus Gidley-Baird | Antibodies against non functional p2x7 receptor |
| JP2010505426A (ja) | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ |
| CA2737126C (en) | 2007-09-14 | 2018-05-01 | Biosceptre International Limited | Novel p2x7 epitopes |
| JP5624885B2 (ja) | 2007-09-14 | 2014-11-12 | バイオセプター・インターナショナル・リミテッド | 細胞外体液中のプリン作動性（ｐ２ｘ）受容体 |
| ES2610225T3 (es) | 2008-07-04 | 2017-04-26 | Biosceptre (Aust) Pty Ltd | Péptidos y epítopos anti P2X7 |
| ES2557456T3 (es) | 2009-08-20 | 2016-01-26 | Biosceptre (Aust) Pty Ltd | Anticuerpos anti-receptor P2X7 y fragmentos de los mismos |
| AU2010336032C1 (en) | 2009-12-24 | 2016-04-21 | Biosceptre International Limited | Antibodies to non-functional oligomeric P2X7 receptors |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| CN106310245A (zh) | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
| US9566318B2 (en) | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
-
2010
- 2010-12-23 AU AU2010336032A patent/AU2010336032C1/en active Active
- 2010-12-23 EP EP17209838.6A patent/EP3321285B1/en active Active
- 2010-12-23 ES ES10838429.8T patent/ES2667003T3/es active Active
- 2010-12-23 BR BR112012015561-0A patent/BR112012015561B1/pt active IP Right Grant
- 2010-12-23 CA CA2784345A patent/CA2784345C/en active Active
- 2010-12-23 WO PCT/AU2010/001741 patent/WO2011075789A1/en not_active Ceased
- 2010-12-23 JP JP2012545019A patent/JP5992831B2/ja active Active
- 2010-12-23 ES ES17209838T patent/ES2732021T3/es active Active
- 2010-12-23 EP EP10838429.8A patent/EP2516470B1/en active Active
- 2010-12-23 CN CN201080063868.6A patent/CN102762595B/zh active Active
- 2010-12-23 US US13/518,382 patent/US8835609B2/en active Active
-
2014
- 2014-08-11 US US14/456,898 patent/US9428587B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515013A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2013502204A5 (enExample) | ||
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| JP2017507652A5 (enExample) | ||
| JP2009532336A5 (enExample) | ||
| JP2017052784A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| RU2017126476A (ru) | Новые модуляторы и способы их применения | |
| JP2014526898A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2013198490A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| JP2015530971A5 (enExample) | ||
| NZ598670A (en) | Antibodies against glucagon receptor and their use | |
| NZ608206A (en) | Antibodies that bind myostatin, compositions and methods | |
| JP2018512379A5 (enExample) | ||
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2020502271A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| JP2017500028A5 (enExample) |